TrialLancet (London, England)2017

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

Meike H van der Ree et al.PubMed ↗Publisher ↗

No numbers read from the abstract.